Clinical trialNCT04499053RecruitingPhase 2Interventional

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

SponsorGeorgetown UniversityEnrollment18Carcinoma, Non-Small Cell Lung

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination with standard chemotherapy is safe and effective for the treatment of stage IV NSCLC in patients with HIV infection.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Chul Kim, MD
Georgetown University
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Chul Kim, MD
Recruiting
Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
Stephen Liu, MD
Recruiting
Harry and Jeannette Weinberg Cancer Institute at Franklin Square
Baltimore, Maryland, United States
Kevin Chen, MD
Recruiting
Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
Katherine Scilla, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Durvalumab →Tremelimumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Dec 2020
Primary completion: 28 Feb 2027
Completion: 31 Dec 2027
Last update posted: 16 Mar 2026
Registered enrollment: 18
Registry id: NCT04499053

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.